JP2019536461A - 養子細胞療法のための操作細胞の産生 - Google Patents

養子細胞療法のための操作細胞の産生 Download PDF

Info

Publication number
JP2019536461A
JP2019536461A JP2019530100A JP2019530100A JP2019536461A JP 2019536461 A JP2019536461 A JP 2019536461A JP 2019530100 A JP2019530100 A JP 2019530100A JP 2019530100 A JP2019530100 A JP 2019530100A JP 2019536461 A JP2019536461 A JP 2019536461A
Authority
JP
Japan
Prior art keywords
cells
cell
antigen
composition
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536461A5 (enExample
Inventor
パスカル ボーシェスン
パスカル ボーシェスン
セミー ユー． タリーン
セミー ユー． タリーン
Original Assignee
ジュノー セラピューティクス インコーポレイテッド
ジュノー セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジュノー セラピューティクス インコーポレイテッド, ジュノー セラピューティクス インコーポレイテッド filed Critical ジュノー セラピューティクス インコーポレイテッド
Publication of JP2019536461A publication Critical patent/JP2019536461A/ja
Publication of JP2019536461A5 publication Critical patent/JP2019536461A5/ja
Priority to JP2022008417A priority Critical patent/JP2022058727A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
JP2019530100A 2016-12-05 2017-12-05 養子細胞療法のための操作細胞の産生 Pending JP2019536461A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022008417A JP2022058727A (ja) 2016-12-05 2022-01-24 養子細胞療法のための操作細胞の産生

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662430349P 2016-12-05 2016-12-05
US62/430,349 2016-12-05
PCT/US2017/064778 WO2018106732A1 (en) 2016-12-05 2017-12-05 Production of engineered cells for adoptive cell therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022008417A Division JP2022058727A (ja) 2016-12-05 2022-01-24 養子細胞療法のための操作細胞の産生

Publications (2)

Publication Number Publication Date
JP2019536461A true JP2019536461A (ja) 2019-12-19
JP2019536461A5 JP2019536461A5 (enExample) 2021-01-21

Family

ID=60935957

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530100A Pending JP2019536461A (ja) 2016-12-05 2017-12-05 養子細胞療法のための操作細胞の産生
JP2022008417A Pending JP2022058727A (ja) 2016-12-05 2022-01-24 養子細胞療法のための操作細胞の産生

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022008417A Pending JP2022058727A (ja) 2016-12-05 2022-01-24 養子細胞療法のための操作細胞の産生

Country Status (11)

Country Link
US (1) US20190350978A1 (enExample)
EP (1) EP3548611A1 (enExample)
JP (2) JP2019536461A (enExample)
KR (1) KR20190098747A (enExample)
CN (1) CN110249046A (enExample)
AU (1) AU2017370644A1 (enExample)
BR (1) BR112019011207A2 (enExample)
CA (1) CA3045338A1 (enExample)
MA (1) MA46998A (enExample)
MX (1) MX2019006438A (enExample)
WO (1) WO2018106732A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512071A (ja) * 2020-01-30 2023-03-23 ウモジャ バイオファーマ， インコーポレイテッド 二特異性形質導入エンハンサー

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
SI3844267T1 (sl) * 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
US20210171909A1 (en) * 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
WO2020092696A1 (en) * 2018-10-31 2020-05-07 Musc Foundation For Research Development Ex vivo activation and expansion of t cells for adoptive cell transfer therapy
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
US10918667B2 (en) * 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
CN113365654A (zh) * 2019-01-29 2021-09-07 Gpb科学有限公司 具有改进的生产和治疗特征的细胞群
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2020210678A1 (en) * 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP4778585A2 (en) 2019-05-07 2026-07-22 Gracell Bioscience (Shanghai) Co., Ltd. Engineered immune cell targeting bcma and use thereof
CN113966394A (zh) * 2019-05-28 2022-01-21 美天施生物科技有限两合公司 产生遗传修饰的t细胞的方法
US12702708B2 (en) 2019-08-21 2026-08-11 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
CN114600172A (zh) * 2019-08-30 2022-06-07 朱诺治疗学股份有限公司 用于将细胞分类的机器学习方法
JP7805928B2 (ja) 2019-11-26 2026-01-26 ノバルティス アーゲー Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
IL294874B1 (en) * 2020-01-21 2026-06-01 Takeda Pharmaceutical Co Limited Preparations and methods for cryopreservation of cells
CN115003818A (zh) * 2020-01-22 2022-09-02 科济生物医药（上海）有限公司 病毒载体转导细胞的方法
CA3169243A1 (en) * 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CA3169672A1 (en) * 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
WO2021188840A1 (en) * 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
JP2023526156A (ja) * 2020-03-20 2023-06-21 アメリカ合衆国 免疫療法のためのｔ細胞及びｔ細胞受容体を単一細胞解析により腫瘍から単離する方法
WO2021231806A1 (en) 2020-05-13 2021-11-18 Rapa Therapeutics, Llc Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
CN112831525A (zh) * 2020-10-21 2021-05-25 东莞清实生物科技有限公司 一种简单高效的慢病毒冻存液及其应用
KR20230151513A (ko) * 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Cd8 표적 바이러스 벡터의 용도
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
JP2024532963A (ja) 2021-04-08 2024-09-11 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ８特異的抗体コンストラクト及びその組成物
GB202105113D0 (en) * 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
WO2022246041A2 (en) * 2021-05-20 2022-11-24 Achelois Biopharma, Inc. Compositions and methods for multivalent surface display on enveloped particles
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
CN113846099B (zh) * 2021-09-23 2022-04-22 中国农业科学院兰州兽医研究所 用于敲低猪SAMHD1基因表达的siRNA、试剂盒及其应用
WO2023205037A1 (en) * 2022-04-17 2023-10-26 Biogen Ma Inc. Methods of delivering nucleotide sequences to cells via simultaneous transduction
AU2023320547A1 (en) * 2022-08-04 2025-02-06 Lyell Immunopharma, Inc. Methods of manufacturing chimeric antigen receptor t cells
EP4602152A1 (en) * 2022-10-10 2025-08-20 Kite Pharma, Inc. New large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection
EP4716851A2 (en) * 2023-05-23 2026-04-01 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
US12595460B2 (en) 2024-04-05 2026-04-07 Applied Cells Inc. Method and apparatus for producing CAR T cells
WO2026136428A1 (en) * 2024-12-18 2026-06-25 Kite Pharma, Inc. High-throughput manufacturing and screening of car-t cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279866A1 (en) * 2006-08-25 2008-11-13 The Brigham And Women's Hospital, Inc. Induction of immunosuppression by inhibition of ATM
US20150024006A1 (en) * 2004-10-14 2015-01-22 Immunovative Therapies, Ltd. Allogeneic cellular immunotherapy for opportunistic infection
WO2015164675A1 (en) * 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
WO2016073602A2 (en) * 2014-11-05 2016-05-12 Juno Therapeutics, Inc. Methods for transduction and cell processing
JP2016528900A (ja) * 2013-08-23 2016-09-23 ザ スクリプス リサーチ インスティテュート 宿主細胞へのレトロウイルスの導入の効率の増強
US20160281111A1 (en) * 2015-03-26 2016-09-29 Editas Medicine, Inc. Crispr/cas-mediated gene conversion

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5565566A (en) 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
ATE112314T1 (de) 1988-05-17 1994-10-15 Lubrizol Genetics Inc Pflanzliches ubiquitinpromotorsystem.
US5298508A (en) 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
AU6781194A (en) 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
US5504090A (en) 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP4431638B2 (ja) 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
ATE186235T1 (de) 1996-04-24 1999-11-15 Claude Fell Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
US6326390B1 (en) 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2224726T3 (es) 1998-12-24 2005-03-01 Biosafe S.A. Sistema de separacion sanguinea indicado en particular para la concentracion de celulas madre hematopoyeticas.
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6313131B1 (en) 1999-02-16 2001-11-06 Upsher-Smith Laboratories, Inc. Method of kidney treatment
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US7078205B2 (en) 2000-02-17 2006-07-18 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
JP3839453B2 (ja) 2002-11-22 2006-11-01 株式会社バイオシンクタンク Ｒｎａ干渉の標的塩基配列検索方法、ｒｎａ干渉を生じさせるポリヌクレオチドの塩基配列設計方法、２本鎖ポリヌクレオチドの作製方法、遺伝子の発現抑制方法、塩基配列処理装置、塩基配列処理方法をコンピュータに実行させるプログラム、記録媒体、および、塩基配列処理システム
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
US20080171951A1 (en) 2005-03-23 2008-07-17 Claude Fell Integrated System for Collecting, Processing and Transplanting Cell Subsets, Including Adult Stem Cells, for Regenerative Medicine
US20080274091A1 (en) * 2005-05-20 2008-11-06 Virxsys Corporation Autologous T Cell Manufacturing Processes
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
WO2011066048A1 (en) 2009-10-22 2011-06-03 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
ES2785081T3 (es) 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2
CN103502439B (zh) 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
US9149519B2 (en) 2012-01-17 2015-10-06 New York University Chimeric human immunodeficiency virus type 1 (HIV-1) with enhanced dendritic cell and macrophage tropism comprising the simian immunodeficiency virus (SIV) minimal Vpx packaging domain
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
WO2013188864A2 (en) 2012-06-15 2013-12-19 Sinomab Bioscience Limited Anti-cd22 anti-idiotypic antibodies and uses thereof
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
IL298125A (en) 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
US9393268B2 (en) 2013-03-15 2016-07-19 Thomas Jefferson University Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
RS62471B1 (sr) * 2014-04-16 2021-11-30 Juno Therapeutics Gmbh Metode, kompleti i uređaji za proširenje populacije ćelija
SG11201608701QA (en) 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP3166968B1 (en) 2014-05-02 2021-09-22 The Trustees of the University of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
EP3172231B1 (en) * 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
RU2716716C2 (ru) 2014-10-27 2020-03-16 Фред Хатчинсон Кэнсер Рисёрч Сентер Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
EP3227323B1 (en) * 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
GB201503500D0 (en) * 2015-03-02 2015-04-15 Ucl Business Plc Cell
CN108884460B (zh) * 2016-03-19 2023-04-28 埃克苏马生物技术公司 淋巴细胞转导及其扩增调节的方法与组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150024006A1 (en) * 2004-10-14 2015-01-22 Immunovative Therapies, Ltd. Allogeneic cellular immunotherapy for opportunistic infection
US20080279866A1 (en) * 2006-08-25 2008-11-13 The Brigham And Women's Hospital, Inc. Induction of immunosuppression by inhibition of ATM
JP2016528900A (ja) * 2013-08-23 2016-09-23 ザ スクリプス リサーチ インスティテュート 宿主細胞へのレトロウイルスの導入の効率の増強
WO2015164675A1 (en) * 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
WO2016073602A2 (en) * 2014-11-05 2016-05-12 Juno Therapeutics, Inc. Methods for transduction and cell processing
US20160281111A1 (en) * 2015-03-26 2016-09-29 Editas Medicine, Inc. Crispr/cas-mediated gene conversion

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E COSTELLO, ET AL.: "Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors", GENE THERAPY, vol. 7, JPN6021041944, 2000, pages 596 - 604, ISSN: 0004969235 *
ODILE DUCREY-RUNDQUIST, ET AL.: "Modalities of Interleukin-7-induced Human Immunodeficiency Virus Permissiveness in Quiescent T Lymph", JOURNAL OF VIROLOGY, vol. 76, no. 18, JPN6021041943, 2002, pages 9103 - 9111, ISSN: 0004622022 *
XIANZHENG ZHOU, ET AL.: "Lentivirus-Mediated Gene Transfer and Expression in Established Human Tumor Antigen-Specific Cytotox", HUMAM GENE THERAPY, vol. 14, JPN6021041945, 2003, pages 1089 - 1105, ISSN: 0004969234 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512071A (ja) * 2020-01-30 2023-03-23 ウモジャ バイオファーマ， インコーポレイテッド 二特異性形質導入エンハンサー

Also Published As

Publication number Publication date
BR112019011207A2 (pt) 2019-10-08
US20190350978A1 (en) 2019-11-21
EP3548611A1 (en) 2019-10-09
JP2022058727A (ja) 2022-04-12
MX2019006438A (es) 2019-11-28
KR20190098747A (ko) 2019-08-22
CA3045338A1 (en) 2018-06-14
WO2018106732A1 (en) 2018-06-14
MA46998A (fr) 2019-10-09
RU2019120834A (ru) 2021-01-12
RU2019120834A3 (enExample) 2021-06-21
CN110249046A (zh) 2019-09-17
AU2017370644A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
JP2022058727A (ja) 養子細胞療法のための操作細胞の産生
US20250171739A1 (en) Process for generating therapeutic compositions of engineered cells
US12215348B2 (en) Methods for producing genetically engineered cell compositions and related compositions
KR102833956B1 (ko) 세포를 배양하기 위한 무혈청 배지 제형 및 이의 사용 방법
KR20220146480A (ko) Ｔ 세포 형질도입 방법
US20250101379A1 (en) Methods of manufacturing cellular compositions
CN114854790A (zh) 病毒载体转导细胞的方法
RU2780156C2 (ru) Продуцирование сконструированных клеток для адоптивной клеточной терапии
RU2790444C2 (ru) Способы получения композиций генно-инженерных клеток и родственных композиций

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230630

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230908